Neurosense Therapeutics LtdNASDAQ:NRSNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.2500
- TODAY'S CHANGE (%)0.0200 (1.6260%)
- Bid / Lots1.2200/ 1
- Ask / Lots1.2600/ 50
- Open / Previous Close1.2500 / 1.2300
- Day Range
- 52 Week Range
- Volume877
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRSN |
|---|---|---|
| 09:32 ET | 177 | 1.25 |
Oct 28, 2024
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 24, 2024
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients, from 8:30AM ET on Thursday Oct 24, 2024 by Dow Jones
8:30AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 15, 2024
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates, from 9:15AM ET on Tuesday Oct 15, 2024 by Dow Jones
9:15AM ET on Tuesday Oct 15, 2024 by Dow Jones
Oct 9, 2024
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada, from 9:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
9:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
Oct 7, 2024
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting, from 9:00AM ET on Monday Oct 07, 2024 by Dow Jones
9:00AM ET on Monday Oct 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurosense Therapeutics Ltd | 23.9M | -2.8x | --- |
X T L Biopharmaceuticals Ltd | 23.7M | -5.4x | --- |
Tempest Therapeutics Inc | 23.7M | -0.6x | --- |
Lisata Therapeutics Inc | 24.2M | -1.1x | --- |
Onconetix Inc | 24.1M | 0.0x | --- |
Athira Pharma Inc | 24.6M | -0.2x | --- |
Company Information
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Contact Information
- Headquarters
- 11 Hamenofim St., Building BHERZLIYA, Israel 4672562
- Phone
- ---
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Mark Leuchtenberger
- Chief Executive Officer, Director
- Alon Ben-Noon
- Chief Financial Officer
- Or Eisenberg
- Chief Medical Officer
- Ferenc Tracik
- Non-Executive Independent Director
- Cary Claiborne
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 19.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.44 |
Book Value | $-0.11 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
